Amarin (AMRN) in Focus as Traders Await NCE Decision on Vascepa
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- US stock futures steady after tech slump; investors focus on Middle East tensions
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- U.S. debt tops $40 trillion
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Marvell issues Google warrant tied to custom chip deal
- Tech selloff weighs down Wall Street as bond yields climb
- FOMC minutes from July 28-29th meeting
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- US stock futures steady after tech slump; investors focus on Middle East tensions
Following Fifth NCE Delay, Amarin (AMRN) Has to Go-It-Alone on Vascepa - MKM
December 17, 2012 12:19 PM ESTMKM Partners commented on Amarin Corporation (NASDAQ: AMRN) Monday after the FDA's Oragle Book Cumulative Supplement for November once again didn't not show a ruling on NCE status for Vascepa. The firm notes this is the fifth delay to the NCE decision.
Based on yet another delay MKM's Jon LeCroy continue to assume that it is unlikely that Amarin will be able to successfully petition the FDA to... More
Amarin (AMRN) Slips as FDA Updates Orange Book
December 14, 2012 2:28 PM ESTAmarin Corp Plc (NASDAQ: AMRN) shares slump in afternoon trading Friday following the FDA updating its Orange Book.
To access the Vascepa page at the FDA, click here.
Shares are down 0.7 percent today.... More
Amarin (AMRN) Receives Notice of Allowance for '450 Patent
December 13, 2012 7:33 AM ESTAmarin Corporation plc (Nasdaq: AMRN) announced today that the United States Patent and Trademark Office (USPTO) has published notification of Notice of Allowance for U.S. Patent Application Serial Number 13/623,450. This application includes claims intended to protect the Vascepa® (icosapent ethyl) indication approved by the U.S. Food and Drug Administration (FDA) based on Amarin's MARINE clinical trial results.
A Notice of Allowance is issued after the USPTO makes a determination that a patent can be granted... More
JPMorgan Doesn't Rule Out Amarin (AMRN) Exploring Sale/Partnership into ANCHOR sNDA, NCE
December 11, 2012 7:58 AM ESTJPMorgan is out with comments on Amarin Corp. (Nasdaq: AMRN) following the company's sales force and financing update for Vascepa last week.
The firm said investors should hang on to the stock moving forward, citing favorable risk-to-reward on the decision. JPMorgan noted that, given the NCE status of Vascepa and that the drug as FDA approval, it is no surprise that the pharma is ready to launch under the MARINE indication. Additionally, ANCHOR is expected to... More
MKM Cuts PT on Amarin (AMRN) to $12; Sees 5% Chance of Partnering on Vascepa Now
December 7, 2012 10:54 AM ESTMKM Partners is keeping its Buy call on Amarin (Nasdaq: AMRN), but cutting its price target by $3 to $12 following Thursday's announcement of new financing and plans to hire more sales staff.
The firm notes that Amarin's moves indicate a "go-it-alone" strategy... More
Lazard Capital Cuts PT on Amarin (AMRN) to $16
December 7, 2012 10:39 AM ESTLazard Capital lowers its price target on Amarin Corporation (NASDAQ: AMRN) from $26 to $16 but maintains its Buy rating after go-it-alone news.
For an analyst ratings summary and ratings history on Amarin Corporation click... More
Canaccord Trims PT on Amarin (AMRN); Sees Increased Commercial Risk, Still Positive on NCE
December 7, 2012 8:43 AM ESTCanaccord Genuity is trimming its price target on Amarin (Nasdaq: AMRN) from $26 down to $19 following news that Amarin is hiring a Vascepa sales force and entering $100 million of new financing, as announced late Thursday. The firm maintains a Buy rating on the stock.
... More
Jefferies Maintains Bullish Stance on Amarin (AMRN) Despite Self Commercialization News
December 7, 2012 8:00 AM ESTJefferies reiterated their Buy and $28 price target on Amarin Corporation (NASDAQ: AMRN) following the company's move to self-commercialize Vascepa.
The firm comments, "AMRN announced a decision to hire a salesforce to launch Vascepa in 1Q13 with a $100m non-dilutive debt... More
Amarin (AMRN) Still Risky into NCE Amid Vascepa Sales Staff Additions, Financing - Analyst
December 7, 2012 7:20 AM ESTAmarin (Nasdaq: AMRN) is in the dumps Friday morning following a news release Thursday night that it was entering a non-equity financing agreement for $100 million and hiring about 250 to 300 reps for its Vascepa launch.
Today, Wedbush is out with some comments on the news today.
Wedbush said the timing of the release was a surprise following... More
Amarin (AMRN) Enters $100M Non-Equity Financing Agreement; Hiring for Vascepa Sales Launch
December 6, 2012 4:03 PM ESTAmarin Corporation plc (Nasdaq: AMRN) announced today a $100 million non-equity financing with an investment fund managed by Pharmakon Advisors and that Amarin is continuing its preparations to commercialize Vascepa® (icosapent ethyl) capsules with the hiring of a sales force in the United States. Payments by Amarin under this hybrid debt-like instrument are expected to be made over a 3.5-year period commencing in November 2013 and to continue through early 2017.
As... More
